Skip to main content
TipRanks
Go Ultimate75% OFF

Aytu BioScience (AY20) Q4 2026 Earnings Report

0 Followers

DE:AY20 Q4 2026 EPS Results

Actual EPS
EUR 0.00
Consensus EPS
-EUR 0.26
Beat/Miss
Beat by +EUR 0.26
One Year Ago EPS
-EUR 2.67

DE:AY20 Q4 2026 Revenue Results

Actual Revenue
EUR 14.68M
Expected Revenue
EUR 11.19M
Beat/Miss
Beat by +EUR 3.49M
YoY Revenue Growth
+6.42%

Earnings Announcement Details

Quarter
Q4 2026
Date
09/22/2026
Time
After Close
Conference Call
Tuesday, September 22, 2026
DE:AY20 Upcoming Earnings

Aytu BioScience's next earnings date is estimated for February 17, 2027, based on past reporting schedules.

Q4 2026 Earnings Call Audio

DE:AY20 Q4 2026 Earnings Call
0:00 / 0:00

Q4 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Sep 22, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call was strongly optimistic, centered on EXXUA's accelerating prescriptions, broadening prescriber and patient adoption, favorable access and gross-to-net performance, and a return to positive fourth-quarter adjusted EBITDA. The company also highlighted resilient legacy products, improved operating cash generation, and debt reduction. Challenges included the early stage of the EXXUA launch, temporary sales-force coverage reductions, year-over-year declines in ADHD and pediatrics revenue, lower gross margin versus the prior year, and expected first-half fiscal 2027 profitability and cash-flow softness. Highlights significantly outweighed the lowlights.

Company Guidance

For fiscal 2027, Aytu is not providing revenue guidance, but its current plan calls for approximately $49 million to $54 million of operating expenses on a GAAP basis and approximately $45 million to $49 million of cash-based operating expenses excluding noncash expenses, including up to $6 million in sales and marketing; research and development expense should remain minimal, and interest expense is expected to continue to decline steadily on a full year basis. Consolidated gross margin is expected to be lowest in the first part of fiscal 2027 and to improve as the year progresses, with a current expectation to approach 66% to 67% gross margin in the fourth quarter of fiscal 2027. Aytu expects lower adjusted EBITDA and operating cash flow in the first half of fiscal 2027 than in the second half, expects the 6-month period ending June 30, 2027, to generate positive adjusted EBITDA, and expects cash flow to improve in the second half.

  • Fourth-Quarter Revenue GrowthFiscal 2026 fourth-quarter net revenue was $16.1 million, up 6% from $15.1 million in the prior-year period and up from $12.4 million in the third quarter, with sequential increases across all three portfolios. Fiscal 2026 net revenue was $57.6 million.
  • EXXUA Revenue and Prescription MomentumEXXUA generated $3.9 million of fourth-quarter net revenue, up from $2.4 million in the third quarter, and contributed $6.6 million for fiscal 2026. Fourth-quarter prescriptions totaled 3,323 versus 1,398 in the March quarter, while monthly prescriptions increased from 973 in April to 1,089 in May and 1,261 in June. Prescriptions rose further to 1,377 in July and 1,408 in August.
  • Strong Recent EXXUA Weekly Prescription PerformanceEXXUA prescriptions reached 394 for the week ending September 4, described as a significant jump from July and August levels and an all-time high weekly prescription level.
  • Improved Sales Force ProductivityUsing monthly sales-force headcount as a directional measure, prescriptions per representative increased from approximately 18 in March to approximately 43 in July, more than a twofold increase. Total monthly prescriptions also increased 81% over that period.
  • Broad EXXUA Territory ContributionTwenty-four territories, approximately 60% of the current sales force, were driving 70% of actual EXXUA prescriptions. Management said this demonstrated breadth across geographies and sales specialists rather than a business concentrated in only a few territories.
  • EXXUA Sales Productivity PotentialManagement stated that 45 territories generating 15 prescriptions per representative per week would equal 675 weekly prescriptions and approximately a $26 million annual run rate at the current selling price. At 20 prescriptions per representative per week, the figures would be 900 weekly prescriptions and approximately a $35 million annual run rate; at 30 prescriptions per representative per week, the annual run rate would exceed $50 million.
  • Growing Prescriber and Patient BaseNearly 1,200 unique prescribers had written EXXUA and nearly 2,500 unique patients had received it. Management reported repeat prescribing, encouraging physician feedback on patient response and tolerability, and growing refill activity.
  • EXXUA Market Opportunity and Product DifferentiationManagement described EXXUA as the first and only selective serotonin 5-HT1A receptor agonist approved by the FDA for major depressive disorder in adults. The estimated U.S. major depressive disorder population is 21 million, and the U.S. prescription MDD market exceeds $22 billion.
  • Favorable EXXUA Gross-to-Net PerformanceEXXUA gross-to-net realization was significantly higher than initial expectations, supported by higher-than-anticipated commercial payer approval rates. Management said approval rates were holding month-to-month, with government business representing well north of 20% to 25% of the business, and noted that there were no commercial contracts or supplemental Medicaid or Medicare rebates.
  • High Prior-Authorization Success RateManagement reported that approval rates for prior authorizations were quite high, with success for claims submitted through the program in the neighborhood of 70%. The company attributed this to the ease of use of its process and the patient population, which often includes people who have taken multiple medications.
  • Positive Adjusted EBITDA in the Fourth QuarterAdjusted EBITDA was positive $0.5 million in the fourth quarter, compared with negative $2.8 million in the third quarter. The company also reported a fourth-quarter net loss of $0.1 million, or $0.00 per share rounded, compared with a $19.8 million net loss, or $2.92 per share, in the prior-year quarter.
  • Improved Operating Cash Generation and DeleveragingFiscal 2026 cash flow from operating activities was $3.3 million versus cash usage of $1.9 million in fiscal 2025, an improvement of $5.2 million. The company reduced its revolving credit facility balance to $6.1 million from $10.4 million at March 31 and repaid the remaining revolver balance after year-end. Fixed payment arrangements had no remaining balance at June 30.
  • ADHD Portfolio Sequential Improvement and DurabilityADHD fourth-quarter net revenue was $10.4 million, up from $9.1 million in the third quarter. Adzenys brand and authorized generic products continued to retain approximately 80% of prescriptions in the market for Adzenys and its generic equivalents. Management said the portfolio remained an important source of profit and cash with limited promotional spending.
  • Cotempla Authorized Generic OpportunityCotempla's authorized generic gained prescriptions week-over-week. Teva had not launched its generic version of Cotempla following the July 1 date permitted under the settlement agreement, presenting potential upside to the company's base-case assumptions around Cotempla's revenue run rate.
  • Pediatrics Portfolio Continued to ContributeThe pediatrics portfolio generated $1.8 million of fourth-quarter net revenue compared with $0.9 million in the March quarter. Management described the mature products as a useful and durable contributor to the legacy business and its financial foundation.
  • Fiscal 2027 Profitability and Margin FrameworkThe company expects approximately $49 million to $54 million of GAAP operating expenses and approximately $45 million to $49 million of cash-based operating expenses in fiscal 2027. It expects consolidated gross margin to approach 66% to 67% in the fourth quarter of fiscal 2027 and expects the six-month period ending June 30, 2027, to generate positive adjusted EBITDA.
  • Continued EXXUA Investment with Financial DisciplineAytu plans to continue investing in EXXUA sales and marketing, medical and scientific education, sales-force coverage, marketing programs, and physician and patient education. Up to $6 million of sales and marketing investment is planned for fiscal 2027, with spending to be managed against prescription trends, access, commercial performance, and available liquidity.
  • Reduced Interest Expense and Higher EquityFourth-quarter interest expense declined to $0.4 million from $0.7 million a year earlier, while full-year interest expense declined to $1.9 million from $3.7 million. Stockholders' equity increased to $35.3 million at June 30, 2026, from $19 million a year earlier, including a noncash $26.4 million reclassification from warrant liabilities to equity.

DE:AY20 Earnings History

DE:AY20 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 17, 20272027 (Q2)-0.14--0.96――
Nov 16, 20262027 (Q1)-0.23-0.18-0.07-150.00% (-0.11)
Sep 22, 20262026 (Q4)-0.260.00-2.67100.00% (+2.67)
May 13, 20262026 (Q3)-0.40-0.480.18-365.00% (-0.67)
Feb 03, 20262026 (Q2)-0.37-0.96-0.26-275.00% (-0.70)
Nov 13, 20252026 (Q1)-0.17-0.07-0.1860.00% (+0.11)
Sep 23, 20252025 (Q4)―-2.67-0.75-257.32% (-1.92)
May 14, 20252025 (Q3)-0.150.18-0.47138.46% (+0.66)
Feb 12, 20252025 (Q2)-0.26-0.26-0.04-600.00% (-0.22)
Nov 13, 20242025 (Q1)-0.31-0.18-1.3586.49% (+1.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed